AI assistant
DEXCOM INC — Director's Dealing 2023
Mar 10, 2023
30198_dirs_2023-03-10_bfa8e03d-7399-41a2-859b-801dcbc68ac8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-03-08
Reporting Person: Flynn Paul R (EVP Global Revenue)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-03-08 | Common Stock | A | 18776 | $0.001 | Acquired | 74520 | Direct |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2: Included in this number are 52,112 unvested restricted stock units, 18,776 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,512 of which were granted on March 8, 2021 and shall vest through March 8, 2024.